In last trading session, Adc Therapeutics SA (NYSE:ADCT) saw 1.64 million shares changing hands with its beta currently measuring 1.92. Company’s recent per share price level of $3.04 trading at -$0.21 or -6.46% at ring of the bell on the day assigns it a market valuation of $301.50M. That closing price of ADCT’s stock is at a discount of -35.86% from its 52-week high price of $4.13 and is indicating a premium of 65.46% from its 52-week low price of $1.05. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.65 million shares which gives us an average trading volume of 716.02K if we extend that period to 3-months.
For Adc Therapeutics SA (ADCT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
Adc Therapeutics SA (NYSE:ADCT) trade information
Upright in the red during last session for losing -6.46%, in the last five days ADCT remained trading in the red while hitting it’s week-highest on Monday, 07/14/25 when the stock touched $3.04 price level, adding 10.06% to its value on the day. Adc Therapeutics SA’s shares saw a change of -20.42% in year-to-date performance and have moved -3.49% in past 5-day. Adc Therapeutics SA (NYSE:ADCT) showed a performance of -15.08% in past 30-days. Number of shares sold short was 4.53 million shares which calculate 4.89 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 8 to the stock, which implies a rise of 62.0% to its current value. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 13. It follows that stock’s current price would drop -130.26% in reaching the projected high whereas dropping to the targeted low would mean a loss of -130.26% for stock’s current value.
Adc Therapeutics SA (ADCT) estimates and forecasts
This year revenue growth is estimated to rise 9.19% from the last financial year’s standing.
5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 17.78M for the same. And 5 analysts are in estimates of company making revenue of 18.32M in the next quarter. Company posted 17.41M and 18.46M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 1.38% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 8.89% while estimates for its earnings growth in next 5 years are of 16.36%.
Adc Therapeutics SA (NYSE:ADCT)’s Major holders
Insiders are in possession of 21.59% of company’s total shares while institution are holding 67.58 percent of that, with stock having share float percentage of 86.19%. Investors also watch the number of corporate investors in a company very closely, which is 67.58% institutions for Adc Therapeutics SA that are currently holding shares of the company. REDMILE GROUP, LLC is the top institutional holder at ADCT for having 15.27 million shares of worth $48.25 million. And as of 2024-06-30, it was holding 15.9568 of the company’s outstanding shares.
The second largest institutional holder is PROSIGHT MANAGEMENT, LP, which was holding about 9.57 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.0009 of outstanding shares, having a total worth of $30.24 million.
On the other hand, iShares Trust-iShares Russell 2000 ETF and Fidelity Salem Street Trust-Fidelity Small Cap Index Fund are the top two Mutual Funds which own company’s shares. As of May 31, 2025 , the former fund manager was holding 1.93 shares of worth $5.86 million or 1.94% of the total outstanding shares. The later fund manager was in possession of 821.09 shares on Apr 30, 2025 , making its stake of worth around $2.5 million in the company or a holder of 0.83% of company’s stock.
